Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Baxter
AstraZeneca
Chubb
Fuji
Harvard Business School
Healthtrust
Boehringer Ingelheim
Daiichi Sankyo

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,569,612

« Back to Dashboard

Which drugs does patent 7,569,612 protect, and when does it expire?

Patent 7,569,612 protects FIBRICOR and is included in one NDA.
Summary for Patent: 7,569,612
Title:Methods of use of fenofibric acid
Abstract:Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Inventor(s): Arnold; Kristin Anne (Morrisville, PA), Feng; Hengsheng (Cherry Hill, NJ)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:12/141,377
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,569,612

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Aralez Pharms Inc FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS ➤ Try a Free Trial
Aralez Pharms Inc FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,569,612

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,741,373 Methods of use of fenofibric acid ➤ Try a Free Trial
7,915,247 Methods of use of fenofibric acid ➤ Try a Free Trial
7,741,374 Methods of use of fenofibric acid ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
AstraZeneca
Chinese Patent Office
Medtronic
Baxter
Johnson and Johnson
Argus Health
Harvard Business School
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.